A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Melphalan (EVOMELA)

Melphalan damages cancer cell DNA to prevent tumor growth.

First FDA approval2013-01-10
Generic availableYes · 12 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$3,267 in CY2023 Part D spend28 claims · — beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Melphalan used for?

Melphalan damages cancer cell DNA to prevent tumor growth.

Is there a generic for Melphalan?

Yes. 12 ANDAs filed at FDA, 12 generic manufacturers currently shipping.

How much does my plan pay for Melphalan?

NADAC pricing data not currently available for this drug.

Is Melphalan on the FDA shortage list?

No. Melphalan is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2023) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.